{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:16:53Z","timestamp":1790543813544,"version":"4.1.0"},"reference-count":0,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AOTT"],"abstract":"<jats:p>Abstract\n\nObjective: The aim of this study was to examine the level of compliance and persistence in patients with postmenopausal osteoporosis (OP) receiving daily risedronate (5 mg) with either fixed dosing of three different timing regimens (A: before breakfast; B: in-between meals; C: before bedtime) or with flexible dosing and the effect on urinary N-terminal telopeptide of Type 1 collagen (NTX-1).\n\nMethods: The study included 448 patients with postmenopausal OP. Patients were randomly assigned into six treatment groups each with a permutation of the treatment sequence (ABC, BCA, etc.) in the crossover phase (3x1 week) and randomized to 23 weeks of either the daily flexible (either regimen A, B or C) or fixed timing (only regimen A, B, or C) in the patient\u2019s preference phase. Urinary NTX-1 was tested.\n\nResults: A total of 433 patients participated in the patient\u2019s preference phase (49.7% preferred flexible and 50.3% fixed timing). There was no significant difference between the proportion of responders who were both compliant and persistent in the flexible (54.4%) and fixed regimens (53.7%) (p=0.8803). A significant difference between the flexible and fixed regimens was seen in persistence in favor of the flexible regimen (p=0.0306). There was no significant difference between the flexible and fixed regimens in terms of compliance (p=0.4611). Change in urinary NTX-1 did not show any difference between the two regimens. At the final visit, 51% of patients in the flexible and 55% in the fixed regimen group considered the used risedronate regimen as excellent or very good (p=0.1440).\n\nConclusion: A flexible dosing with daily risedronate appears be a valuable option in terms of compliance and persistence for patients with postmenopausal OP.\n\n \n\n\u00d6zet\n\n \n\nAma\u00e7: \u00c7al\u0131\u015fman\u0131n amac\u0131 g\u00fcnl\u00fck risedronat (5 mg) tedavisini \u00fc\u00e7 farkl\u0131 zaman rejiminde (A, \u2018kahval\u00act\u0131dan \u00f6nce\u2019; B, \u2018\u00f6\u011f\u00fcnler aras\u0131\u2019; C, \u2018yatmadan \u00f6nce\u2019) olmak \u00fczere sabit doz \u015feklinde veya esnek doz bazl\u0131 alan hastalarda tedaviye uyum ve devam etme d\u00fczeylerini de\u011ferlendirmekti. Ayr\u0131ca hastalar\u0131n doz re\u00acjimlerine y\u00f6nelik tercihleri ve doz rejimlerinin idrar NTX-I d\u00fczeyi \u00fczerine etkileri de de\u011ferlendirildi.\n\n\u00c7al\u0131\u015fma plan\u0131: \u00c7al\u0131\u015fma 448 hastan\u0131n her birinin tedavi sekanslar\u0131n\u0131n diziliminin de\u011fi\u015ftirilmesi (per\u00acmutasyon) (ABC, BCA, gibi) ile olu\u015fan alt\u0131 farkl\u0131 tedavi grubundan birine rasgele atand\u0131\u011f\u0131 bir \u00e7apraz tedavi faz\u0131 (3x1 hafta) ve her bir hastan\u0131n g\u00fcnl\u00fck esnek (rejim A,B veya C\u2019den her hangi biri) ve sabit zamanl\u0131 (yaln\u0131zca rejim A, ya da B veya C) rejimlerden birine 23 hafta s\u00fcreyle randomize edildi\u011fi has\u00actan\u0131n tercihi faz\u0131n\u0131 i\u00e7eriyordu.\n\nBulgular: 433 hasta ikinci faza kat\u0131ld\u0131; %49.7\u2019si esnek rejimi ve %50.3\u2019\u00fc sabit rejimi tercih etti. Esnek ve sabit tedavi rejimleri aras\u0131nda bile\u015fik olarak tedaviye hem uyum hem de devaml\u0131l\u0131k g\u00f6steren, olumlu hareket edenler olarak nitelenen hasta oran\u0131 a\u00e7\u0131s\u0131ndan anlaml\u0131 bir fark saptanmazken (s\u0131ras\u0131yla %54.4 ve %53.7, p=0.8803), iki tedavi rejimi aras\u0131nda tedaviye devam etme a\u00e7\u0131s\u0131ndan esnek rejim lehine anlaml\u0131 bir fark belirlendi (p=0.0306). Tedavi uyumu konusunda esnek ve sabit rejimler aras\u0131nda anlaml\u0131 bir farkl\u0131l\u0131k g\u00f6zlenmedi (p=0.4611). \u0130drar NTX-I d\u00fczeylerindeki de\u011fi\u015fiklikler iki rejim aras\u0131nda anlaml\u0131 bir farkl\u0131l\u0131k g\u00f6stermedi. Son vizitte esnek rejim grubundaki hastalar\u0131n %51\u2019i ve sabit rejimdeki hastala\u00acr\u0131n %55\u2019i kullan\u0131lan risedronat rejimini m\u00fckemmel veya \u00e7ok iyi olarak de\u011ferlendirdi (p=0.1440).\n\n\u00c7\u0131kar\u0131mlar: Bu k\u00fc\u00e7\u00fck \u00f6l\u00e7ekli, se\u00e7ilmi\u015f hasta grubundan elde edilen verilere dayan\u0131larak esnek doz g\u00fcnl\u00fck risedronat tedavisinin tedavi uyumu ve devaml\u0131l\u0131\u011f\u0131 a\u00e7\u0131s\u0131ndan kayda de\u011fer bir alternatif sundu\u00ac\u011fu d\u00fc\u015f\u00fcn\u00fclebilir.<\/jats:p>","DOI":"10.3944\/aott.2015.14.0082","type":"journal-article","created":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T02:32:11Z","timestamp":1436409131000},"page":"67-74","source":"Crossref","is-referenced-by-count":4,"title":["Compliance persistence and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter prospective parallel group study"],"prefix":"10.5152","volume":"49","author":[{"given":"Aydan","family":"Oral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Lorenc for the FLINT-ACT Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3111","published-online":{"date-parts":[[2020,2,7]]},"container-title":["Acta Orthopaedica et Traumatologica Turcica"],"original-title":[],"link":[{"URL":"https:\/\/aott.org.tr\/index.php\/pub\/article\/download\/2942\/2895","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:10:06Z","timestamp":1763464206000},"score":1,"resource":{"primary":{"URL":"https:\/\/aott.org.tr\/index.php\/pub\/article\/view\/2942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.3944\/aott.2015.14.0082","relation":{},"ISSN":["2589-1294","1017-995X"],"issn-type":[{"value":"2589-1294","type":"electronic"},{"value":"1017-995X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,7]]}}}